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Neuroblastoma (NB) is a paediatric solid tumour arising from neural crest-derived precursors, and it accounts for 8-10% of all malignancies and 12-15% of cancer-related deaths in children (1). It is characterized by a remarkable clinical heterogeneity and the assessment of the NB-related genetic abnormalities has been helpful in predicting clinical outcome, stratifying patients in different risk classes and designing appropriate treatments (2,3). MYCN amplification at 2p24 is a well-known genetic alteration associated with NB development and progression (4-8), irrespective of age at diagnosis and clinical stage, whose examination is required in NB tumours before treatment begins (9). Indeed, about half of the high-risk aggressive tumours are characterized by the amplification of MYCN gene, an oncogene of the MYC family of transcription factors that controls the expression of many target genes, which in turn regulates fundamental cellular processes including proliferation, cell growth, apoptosis and differentiation (10). 
MicroRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression at  post-transcriptional level, by binding to the complementary sites in the 3’-untranslated region (3’-UTR) of target messenger RNAs (11-13). Currently, more than 1,800 miRNA genes have been identified in the human genome (miRBase release 21.0) (14), and bioinformatics predictions indicate that up to 60% of the protein coding genes may be regulated by miRNAs (15). MiRNAs play a central role in many cellular processes and their aberrant expression has been reported in childhood solid tumours, including NB (16,17). In the latter, by applying miRNA microarrays and high-throughput sequencing technologies, a series of miRNAs have been reported to play a role as oncogenes or tumour suppressors, as reviewed by Mei et al. (18). For example, dysregulation of miR-542-5p is highly correlated with tumour aggressiveness and poor survival (19), whilst miRNA-34a was found to be a potent tumour suppressor molecule (20). Moreover, some miRNA levels seem to have the potential to increase the efficacy of the treatment by regulating the sensitivity of NB cells to cisplatin (21,22).
In the present study, we investigated the expression of miRNAs in NB by using Next Generation Sequencing (NGS) technology, which allows for a comprehensive assessment of the miRNA transcriptome and has the potential to detect miRNA length variations or sequence modifications (isomiRs) as well as novel miRNA sequences. The SOLiD System was used to sequence small RNA (sRNA) libraries from NB tumours with and without MYCN-amplification and from human dorsal root ganglia (DRG) as a control, in order to detect the genome-wide differences in miRNA levels in these two subtypes of NB. The analysis showed that 128 known miRNAs were significantly dysregulated in the NB tumours in comparison to DRG, utilised as a normal control. Interestingly, 23 miRNAs were differentially expressed in MYCN-amplified vs. MYCN-non amplified tumours. Furthermore, 18 new miRNA candidates were detected in NB samples: 10 in the MNAs, 6 in the MNnA samples, and 2 in both tumour subtypes; 2 putative novel miRNAs were found in the DRG. Notably, the Gene Ontology (GO) analysis of the potential targets of the up-regulated and down-regulated miRNAs indicated that many genes belong to biological processes and cellular components that are involved in cell growth, cell shape, protein activity and genomic instability necessary for cancer initiation and progression. Furthermore, analysis with the Kyoto Encyclopaedia of Genes and Genomes (KEGG) web tools revealed significant enrichment in several cancer-related signalling pathways. 
This study provides some improved information about the mechanisms in NB of the miRNA-associated MYCN network that might contribute to the development of novel diagnostic biomarkers and effective therapeutic strategies in this cancer.

Materials and methods
Patient features and normal controls
Twenty-two NB primary tumour samples, equally distributed between MYCN-amplified (MNA) and  MYCN-non amplified (MNnA), were obtained at diagnosis before any treatment from children admitted to the Department of Oncology at Alder Hey Children’s NHS Trust, Liverpool. Histopathological diagnosis was confirmed using immunohistochemistry. Details of the patients are described in Table I. Institutional written informed consent was obtained from the patient’s parents or legal guardians. 
The study underwent ethical review and approval according to the local institutional guidelines (Alder Hey Children's NHS Foundation Trust Ethics Committee, approval number 09/H1002/88).
Human DRG total RNA (Clontech, Mountain View, CA), pooled from normal tissues of 21 male/female Caucasians who had died suddenly, was used as a normal control. DRG were utilised as a normal control because of their neural crest-derived histogenesis (23) and since NB can occasionally arise from these organs (24).

RNA isolation
Tumour samples were frozen in liquid nitrogen immediately after surgical removal and stored at -80°C. Total RNA was isolated by tissues grinded under liquid nitrogen using 1 ml of TRIzol LS Reagent (Life Technologies, Carlsbad, CA) per 50-100 mg of sample according to the manufacturer’s protocol. RNA concentration and purity were measured by NanoDrop2000 (Thermo Fisher Scientific Inc., Waltham, MA), having 260/280 ratio values in the range of 1.9-2.1. 

Small RNA Library Construction and High-Throughput Sequencing 
Total RNA samples (5 g) were enriched for small RNAs up to 200 bp by size selection using Pure Link miRNA Isolation Kit (Life Technologies) and RNA quality was assessed, before and after RNA enrichment, by the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) using a Agilent RNA 6000 Nano and a Agilent Small RNA kit respectively. Enriched RNA samples were processed using the Small RNA Expression Kit according to the manufacturer’s protocol (Small RNA expression kit, rev. B, Applied Biosystems). Briefly, 20 ng of RNA were first hybridized and ligated with the adapter mix “A”, subsequently reverse transcribed and treated with RNAse H. The cDNA libraries were then PCR amplified, purified and size-selected by PAGE, resulting in libraries containing inserted small RNA sequences of 20-40 bp length. Size, integrity and purity of the libraries were verified by the Agilent 2100 Bioanalyzer, Agilent DNA 1000 kit. The cDNA libraries were barcoded using the SOLiD RNA barcoding kit and amplified onto beads using emulsion PCR. Templated beads were deposited on slides and analysed using the Applied Biosystems SOLiD 4 Sequencer.

Quantification of known microRNAs 
The qualified clean reads were mapped and analysed with the 'small RNA' bioinformatics pipeline from the Thermo Fisher Lifescope version 2.5.1 software (https://www.thermofisher.com/it/en/home/technical-resources/software-downloads/lifescope-genomic-analysis-software.html), using as a target the human genome GRCh38/hg38 and the dataset of mature and precursor miRNA sequences (miRBase, release 21.0) (25). Any sequence match against repetitive elements of the genome (SINEs, LINEs, etc.), and against non-miRNA small RNAs (snoRNAs, piRNAs, tRNAs, rRNA fragments, etc.) were filtered out from the results.
Sequence counts were extracted and reformatted with Genomnia Perl scripts from the pipeline output. Differential expression analysis was performed with the edgeR Bioconductor statistical library version 3.1.0 on R (26) incorporated in a proprietary Genomnia pipeline. TMM-normalized sequence counts in the libraries were transformed in Counts Per Millions (CPM) according to the formula: CPM = (transcript normalized counts/total miRNA matches) *1,000,000. After having estimated the tagwise dispersion, genewise exact test (26) as implemented in edgeR was used to measure the significance of differential expression, using the miRNA “Pseudo-counts”. Sequences were filtered out to remove poorly expressed microRNAs (i.e. miRNAs with less than 10 CPM in more than half of the samples). MiRNAs were called as significantly differentially expressed if the False Discovery Rate (p-value corrected for multiple comparison with the Benjamini-Hochberg procedure) obtained with this method was < 0.05. The MNA vs. MNnA comparison was also performed with the edgeR "Generalized Linear Model" mode optimized for the analysis of data with sequence spikes (27), in order to confirm the obtained results with a second robust statistical approach well suited to handle outlier data.

miRNA target prediction, functional annotation and promoter motif discovery
For each differentially expressed miRNA, a list of experimentally validated targets was extracted form miRTarBase release 6 (http://mirtarbase.mbc.nctu.edu.tw/ (​http:​/​​/​mirtarbase.mbc.nctu.edu.tw​/​​)) (28). In addition, de novo target prediction was performed using the miRanda software (29) on selected down-regulated and up-regulated microRNAs from the comparison MNA vs. MNnA. The 3’UTR sequences of all human transcripts present in Ensembl (release 78) were used as a target set for this analysis, and only predictions with total score ≥ 155 and total energy ≤ -20 were considered as putative miRNA targets. Annotation and enrichment of functional pathways and ontology terms associated with the selected target genes were evaluated using DAVID Bioinformatics Resources 6.7 (30). The same target gene list was used as the starting dataset for the generation of a Functional Interaction network analysis and related Gene Ontology enrichment analysis with the Cytoscape Reactome FI plugin (31,32). Promoter regions of the differentially expressed miRNAs in the comparison MNA vs. MNnA were scanned for motifs by FIMO 4.10.2 software (http://meme-suite.org/tools/fimo) (33). A sequence of 5 Kb was considered as putative upstream regulatory region for each miRNA or miRNA cluster based on the histone acetylation track (H3K27Ac) reported in UCSC. Finally, the MYCN binding motifs available in JASPAR CORE database (http://jaspar.genereg.net/) were used in the promoter analysis. 

Identification of isomiRs and prediction of novel microRNAs
The alignment files in BAM format corresponding to the same biological group (MNA, MNnA and Control) were merged and converted to SAM (Sequence Alignment/Map) format with samtools (34). The files were then processed and analysed with the miRDeep2 software for miRNA prediction (35). The differential expression analysis for isomiRs was carried out with edgeR from Bioconductor, with the same analytical strategy described previously. A set of potentially novel microRNAs was also identified, by selecting among miRDeep2 predictions the hairpins with a probability greater than 60% to be a true positive. Their expression was also evaluated in all samples. MiRNA extraction, library preparation, sequencing and bioinformatics analysis were performed by Genomnia s.r.l. 

Quantitative Real Time PCR (Q-PCR) 
Quantitative Real Time PCR (Q-PCR) was performed to validate some results obtained from the high-throughput sequencing. In brief, step-loop reverse transcription and Q-PCR were carried out using TaqMan MicroRNA Assays (Life Technologies) specific for human miR-18a-5p, miR-217, miR-491-5p and miR-628-3p, according to the manufacturer’s protocol. Ct values for miRNAs were normalized against U6 small nuclear RNA (RNU6) levels, used as an internal control. The relative expression of each miRNA was calculated by the comparative Ct method and expressed as fold change. All samples were run in triplicate reactions in the StepOne Real Time System (Life Technologies) instrument. Results were expressed as means ± standard deviation (SD), and a p-value < 0.05 was considered statistically significant.

Cell lines 
The MYCN-amplified KCNR cell line was grown in RPMI-1640 medium supplemented with 10% foetal bovine serum (FBS), 1% v/v non-essential aminoacid solution, 2 mM glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. HEK (human embryonic kidney) 293T cells were cultured in high-glucose DMEM, supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. All cell lines were maintained in a humidified incubator at 37°C and 5% CO2, and appropriately sub-cultured before confluence was reached. 

Plasmid construction and luciferase assays
The 3’UTR region of the human MYCN gene (3HSAR055440 derived from http://utrdb.ba.itb.cnr.it/) was amplified from genomic DNA using a proof reading Phusion High-Fidelity PCR master mix (Finnzymes, Espoo, Finland) with the following primers: MYCN 3’UTR-F 5’-GCTCTAGAACGCTTCTCAAAACTGGACAGTCAC-3’ and MYCN 3’UTR-R 5’-GCTCTAGAAACATGAGGTATTTCAAAGTGCTATAAGATGC-3’. The 880 bp amplified product was inserted into the XbaI site (underlined primer sequences) of the pRLTK vector (Promega) immediately downstream of the Renilla luciferase gene. The luciferase reporter construct, termed pMYCN-3’UTR, was validated by specific restriction digestions as well as bi-directional sequencing by Bio-Fab Research (RM, Italy). HEK293T were plated at a density of 1.5x105/well in 24-well plates and co-transfected after 24 hours with 50 ng of pMYCN-3’UTR Renilla luciferase construct, 10 ng of reference Firefly luciferase reporter (pGL3-SV40, Promega) and 100 nM of mir-628-3p (mirVana miRNA mimic - MI0003642/MIMAT0003297 by ThermoFisher) or miR-Ctr (miRIDIAN microRNA Mimic Negative Control #1, Dharmacon) molecules using 2 l of Lipofectamine 2000 (Invitrogen). Cells were lysed 72 h after transfection and luciferase signals were detected by the Dual Luciferase Reporter Assay (Promega) using the GloMax Discover System (Promega), following the manufacturer’s instructions. Renilla luciferase activity was normalized to the Firefly luciferase activity for each reaction. Two independent experiments were carried out, each in triplicate. All the luciferase data were expressed as the mean ± SD normalized to the negative control miRNA.

Protein extracts and Western blotting analysis
KCNR cells were seeded at 6.0x105/well in 12-well plates and transfected the day after with miR-628-3p or miR-Ctr (50 mM final concentration) using Lipofectamine 2000, according to manufacturer's instructions. After 72 h, protein expression was determined by Western blotting as previously described (36) with a primary antibodies against MYCN (1:1000, Santa Cruz Biotechnology). Tubulin (Sigma-Aldrich, St Louis, MO, USA) was used as a normalization control for equal loading. Chemiluminescent signals were revealed by ChemiDoc XRS+ System (Bio-Rad) and densitometric analysis was performed by Image Lab 5.1 software (Bio-Rad). 

Results and discussion
Identification and quantification of annotated miRNAs
Comprehensive miRNA, isomiR and novel miRNA identification, annotation and analysis were developed in the framework of this project and are summarized in Figure 1. The miRNA transcriptome was profiled by sequencing of mature miRNA molecules in a panel of primary NB tumours, 4 with MYCN-amplification (MNA) and 4 without MYCN-amplification (MNnA), and from normal dorsal root ganglia (DRG). The clinical characteristics of the patients are reported in Table I. Small RNA libraries were prepared and deep sequenced by using a SOLiD 4 Sequencer platform. About 71 million reads mapped with high quality against the human reference genome (GRCh38/hg38, repeat masked), with an average of 8 million reads per library. The reads corresponding to annotated miRNAs were identified by mapping all reads against the human precursor and mature sequences included in miRBase v21.0. Figure 2A shows that a total of 532 distinct known miRNAs had on average at least 10 read counts in the NB tumour samples, while 512 miRNAs were detected in the DRG sample. 382 of these were expressed in both conditions, with a 72% overlap for NB miRNAs and 75% overlap for DRG miRNAs. Thus, about a quarter of the identified known microRNAs were uniquely expressed in NB or control samples. NB-specific miRNAs might therefore play an important functional role in tumour development and progression, through the regulation of downstream targets and the biological pathways affected by these genes.

Differential expression analysis of miRNAs in NB vs. DRG and functional annotation analysis 
Based on the high-throughput sequencing of small RNAs, we performed differential expression analysis of miRNAs comparing the two libraries from NB tumours (MNA and MNnA collectively considered) and DRG, after removing poorly expressed miRNAs. Of a total of 198 differentially expressed miRNAs in the dataset, 128 (64.6%) displayed statistically significant differential levels in NB tumours in comparison with DRG, after FDR correction. Notably, out of these 128, 47 miRNAs (36.7%) were expressed at higher levels in NBs (Table IIA), whilst 81 (63.3%) were expressed at lower levels (Table IIB). Figure 2B shows the distribution of the different mature miRNA species in abundance classes comparing NB tumours (MNA and MNnA collectively considered) against DRG, allowing a survey of the whole miRNA population. Significantly dysregulated miRNAs are indicated in red. Among the differentially expressed miRNAs, some have been previously associated with NB development, like the up-regulated miR-876-5p, miR-19a, as well as the down-regulated miR-183-5p, miR-423-3p and miR-92b-3p (18,36-39). Other miRNAs have been implicated in the pathogenesis of many types of human cancer but not in NB malignancy until now. In particular, of main interest are the up-regulated miR-127-5p, miR-369-3p and miR-655-3p encoded in the large 14q32 miRNA cluster and associated with oligometastases through repression of shared target genes involved in cytoskeletal organization, cell motility and TGF-beta signalling pathways (40). Also the marked down-regulation of miR-328-3p in NB samples in comparison to DRG suggests its possible role as tumour suppressor also in this malignancy as already observed in other types of cancers, such as acute myeloid leukaemia, chronic myelogenous leukaemia and glioblastoma (41,42). Therefore, future experiments will address the role of this miRNA in the proliferation, invasion and metastasis formation of NB tumour cells. Another new attractive result is the significant down-regulation of miR-1247-5p, whose repression has been demonstrated to play an important role in pancreatic cancer (43,44). Interestingly, the molecular mechanisms underlying miR-1247-5p role have been correlated with its capacity to directly target and silence the expression of neuropilins (44), which are transmembrane glycoproteins recently implicated in tumour functions and found as promising drug target candidates in leukaemia and lymphoma (45). Furthermore, miR-1247-5p also belongs to the 14q32 miRNA cluster (but in reverse strand respect to above mentioned miR-127-5p, miR-369-3p and miR-655-3p) and its aberrant expression in colorectal cancer has been linked to hyper-methylation, confirming the importance of epigenetic modifications in miRNA-mediated cancer development (46). Since alterations in DNA methylation are frequent in NB and can also modulate sensitivity to cytotoxic agents (47), the analysis of the miR-1247-5p promoter region in NB samples could provide new insight into the mechanisms that correlate epigenetic processes and NB development.
To investigate the biological implications of the dysregulated miRNAs, we assessed miRNA target genes within the regulatory network for enrichment in Gene Ontology (GO), one of the most useful methods for functional annotation and classification of gene products. GO categories of the targets of the differentially up-regulated and down-regulated miRNAs (NB vs. DRG) were organized into three different functional groups, i.e. Biological process, Cellular component and Molecular function (Figure 3), among which a significant over-representation of transcription factor activity/binding, protein kinase activity, chromatin modifications, metabolic processes, cell communication, plasma membrane, cytoplasm/intracellular organelle part, cell proliferation and programmed cell death regulation were found. To further explore the biological pathways potentially affected in NB development, the targets of the differentially up-regulated and down-regulated miRNAs (NB vs. DRG) were subjected to KEGG pathway analysis. Several cancer-related networks, including TGF-beta, Neurotrophin, MAPK, ErbB, Toll-like receptor and p53 signalling pathways, were significantly enriched (Tables III-IV). Indeed, the expression levels of TGFBR2, SMAD2 and SMAD4, three important components along the TGF-beta cascade, were found to be down-regulated in NB cells (48). VEGF, Wnt, JAK-STAT, and GnRH pathways were found among the targets of the under-expressed miRNAs in accordance with their growth-inhibitory potential on NB cells (49-51). Moreover, some biological processes linked to cell cycle, adherents junction and focal adhesion could have also been altered. KEGG database interrogation also suggested that many of the miRNA targets contribute to the development of other human tumours, including colorectal cancer, pancreatic cancer, melanoma and gliomas. 

Differential expression analysis of miRNAs in NB with or without MYCN amplification
The miRNA expression profiles of MNA and MNnA tumours largely overlapped as shown by Venn diagram (Figure 4A), suggesting that only a small number of miRNAs are specific for each subgroup. After removing poorly expressed miRNAs, 70 molecules were found to be differentially expressed between MNA and MNnA tumours. Of these, 23 had a p-value lower than 0.05 after FDR correction: 17 miRNAs were significantly up-regulated in MNA samples, while 6 miRNAs were significantly down-regulated (Table V). The most homogeneously expressed molecules among different tumours inside each subgroup were miR-16-2-3p, miR-18a-5p, miR-217, miR-338-5p, miR-489-3p, miR-491-5p, miR-628-3p, miR-628-5p and miR-3065-3p (data not shown). Among these, miR-18a-5p, miR-217, miR-491-5p and miR-628-3p were selected as candidates to validate the miRNA expression data by Q-PCR experiments in the 8 deep-sequencing-analysed NB tumours and in 14 additional NB samples as well as in 4 human NB cell lines (MNA LAN5 and KCNR and MNnA SH-SY5Y and SK-N-SH). Q-PCR demonstrated that the expression levels of the selected dysregulated miRNAs showed strong overlap with the deep-sequencing findings, thus confirming the over-expression of miR-18a-5p and miR-217 as well as the down-regulation of miR-491-5p and miR-628-3p in the MNA (Figure 4B) in comparison with the MNnA tumours. The same trend was found in MNA vs. MNnA NB cell lines (data not shown). The differential expression of a substantial number of miRNAs between favourable and unfavourable NBs was consistent with previous reports (Table V), reinforcing their fundamental role in NB development (18,48,52,53,56,62,63,74,76). In particular, our study confirms how the majority of the differentially expressed miRNAs positively correlated with MYCN amplification, suggesting that miRNA induction might be a general mechanism caused by MYCN oncogene in high-risk NB tumours. Additionally, bioinformatics analysis of the promoter regions of the over-expressed miRNAs identified MYCN binding sites (38,54) in 5 out of 17 miRNAs (Table V), and this is consistent with a direct transcriptional regulation of these molecules by MYCN. Overexpression of miR-17-5p, miR-18a-5p, miR-20a-5p and miR-92a-3p, belonging to the polycistronic miR-17-92 cluster at 13q31.3, was consistently higher in MNA cell lines compared to the MNnA tumours as previously reported (55,56) and in line with the evidence that MYCN directly activates miR-17-92 expression in NB cell lines (55). Indeed, the miR-17-92 cluster has a unique promoter control region and encodes for a precursor transcript that contains six tandem-loop hairpin structures, which in turn produce the six mature molecules miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a-1 (57,58). These miRNAs may act independently or synergistically to target multiple mRNAs encoding for proteins implicated in cancer-related pathways (57,58). Given the miR-17-92 oncogenic role, inhibition of the clustered oncomiRs by delivering single-stranded antisense oligonucleotides (59) may represent a novel and attractive treatment approach for NB therapy. Regarding this aspect, Fontana et al., (60) demonstrated that in vitro and in vivo treatment of MNA NB cells with a specific antagomiR against miR-17-5p was able to dramatically reduce proliferation and to activate massive apoptosis through p21 and BIM over-expression, respectively. Concerning some down-regulated miRNAs in MNA tumours, our data are in agreement with recently published studies. In particular, miR-491-5p was found to be significantly down-regulated at NB metastatic sites compared with primary tumours by Guo et al., (61), and miR-628 was confirmed to be moderately expressed in favourable NBs and nearly absent in unfavourable cases, thus supporting its tumour suppressive function and its potential as a good candidate in discriminating between these two NB subsets (38,62,63). Indeed, among the down-regulated miRNAs, miR-628-3p has one pairing region at position 718-724 of the MYCN 3’ untranslated region (3’UTR, Figure 5A), as predicted by Miranda software (best score ≥ 120). To verify whether miR-628-3p was able to directly target MYCN mRNA, HEK293T cells were co-transfected either with a reporter construct containing 880 base pairs of the human MYCN 3’UTR downstream of the Renilla luciferase open reading frame (Figure 5A) with either miR-628-3p mimic or negative control miRNA (miR-Ctr). Over-expression of miR-628-3p upon transfection was confirmed by Q-PCR assays (data not shown). Luciferase activity was specifically reduced of about 35% (p < 0.01) in cells transfected with miR-628-3p compared to the control group (Figure 5B), thus indicating that miR-628-3p functionally interacts with the MYCN 3'UTR and decreases the expression of the corresponding protein. Indeed, miR-628-3p mimics transiently introduced into KCNR cells, an in vitro model of MNA NB, were able to slightly reduce endogenous MYCN protein levels as compared with miR-Ctr positive samples (Figure 5C), suggesting a functional role of miR-628-3p in MYCN gene expression. Finally, our analysis identified a set of differentially expressed miRNAs, such as miR-130b-5p, miR-217, miR-3065-3p and miR-3182, known as oncomiRs in several other tumours (64-67), but whose role in NB has not yet been investigated (Table V). Interestingly, miR-130b and miR-301b belong to the same genomic cluster located on chromosome 22 and are significantly up-regulated in triple-negative (lacking the expression of the oestrogen receptor, the progesterone receptor and the human epidermal growth factor receptor 2) breast cancer (64), having a direct role in the cyclin G2 regulation. MiR-338 and miR-3065 belong to the brain-specific genomic cluster located on chromosome 17 in an intronic region within the apoptosis-associated tyrosine kinase (AATK) gene, thus having a tumour suppressor function (68). Accordingly, it was described that miR-338-3p strand has the potential to inhibit cell proliferation, cell migration and invasion in human NB cells by affecting the PTEN/Akt pathway (69). MiR-3065 was recently mapped to the antisense strand of miR-338 (70) and regarded as a novel promising candidate contributing to clear cell renal cell development (71). Furthermore, our miRNA promoter in silico analysis showed that also the down-regulated miR-338-5p, miR-489-3p, miR-628-3p and miR-3065 harbour putative MYCN binding motifs in their regulatory regions (Table V), suggesting an inverse correlation and possible feedback regulatory circuits between MYCN amplification and the reduced levels of these miRNAs. To this concern, recent studies have supported the dual role of MYCN in controlling gene expression, being not only a transcriptional activator but also a mediator of transcriptional silencing by facilitating DNA methylation (54,72,73). So, it will be interesting to characterise the molecular mechanisms that regulate miRNA expression.

miRNA target prediction and functional annotation in NBs with or without MYCN amplification
Using the miRTarBase web tool, we found a relevant number of cancer-related genes, such as PTEN, KRAS, EZH2, etc. among the validated target genes for the differentially expressed miRNAs. Indeed, since the availability of experimentally validated targets in miRTarBase was variable and possibly biased towards the more extensively investigated miRNAs, we decided to extend our analysis and perform a de novo target prediction using the miRanda software. In particular, we considered miRNAs with a homogeneous expression level between tumours inside each group: the up-regulated miR-16-2-3p, miR-18a-5p, miR-217 and the down-regulated miR-338-5p, miR-489-3p, miR-491-5p, miR-628-3p, miR-628-5p and miR-3065-3p. The 3’UTR sequences of all human transcripts present in Ensembl were screened for the identification of putative microRNA binding sites: a total of 867 putative target genes were identified for the up-regulated miRNAs, whilst 2148 target genes were identified as potentially modulated by the down-regulated miRNAs. The predicted targets were grouped into functional modules on the basis of their functional interactions, and for each module an enrichment analysis was performed with the Cytoscape Reactome FI plugin. Figure 6 shows the main functional module putatively regulated by miR-16-2-3p, miR-18a-5p and miR-217, which are over-expressed in MNA tumours. The different interaction networks are enriched in gene products implicated in cancer-related biological processes, such as DNA-repair and apoptosis, as well as axon guidance, adenylate cyclase activity and the FGFR signalling pathway. Target genes associated to each specific over-expressed miRNA are reported in Table VI. The GO categories associated with the predicted miRNA targets showed significant overlap with biological processes that are over-represented in the MYCN target genes (38), confirming the existence in NB of a miRNA:MYCN related network able to broadly perturb gene expression (38,74,75). Figure 7 shows the main functional module putatively regulated by miR-338-5p, miR-489-3p, miR-491-5p, miR-628-3p, miR-628-5p and miR-3065-3p which are under-expressed in MNA samples. The enriched interactions consist of proteins involved in synaptic transmission as well as TLR and EGFR signalling pathways. Target genes associated to each specific down-regulated miRNA are reported in Table VII. The complete list of network modules and GO BP - pathway enrichment is included in the Table VIII. Our results suggest that the selected differentially expressed miRNAs are relevant in NB biology and could be of potential importance to stratify high-risk and low-risk tumours. Further investigations will be necessary to validate the specific target genes and to assess the downstream effects.

IsomiRs and novel miRNAs




In this study, NGS technology and bioinformatics analysis allowed to identify a specific set of miRNAs that are differentially expressed in NB tumours compared to DRG, or in NB tumours with or without MYCN amplification. A relevant percentage of these microRNAs has been already found to be involved in NB, another percentage has been shown to be involved in the pathogenesis/progression of other tumours, whilst other miRNAs are new. Target prediction and functional annotation highlighted the possible roles of the identified microRNAs, and in vitro assays provided the first evidence of the miR-628-3p contribution to MYCN regulation. New potential miRNA candidates not previously reported were also found, but further studies are needed to clarify their role in NB development.
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Figure 1 Flow chart of the bioinformatic analyses performed in this study. 

Figure 2 (A) Overlap of expressed known miRNAs (with at least 10 read counts) in a given biological condition. NB tumours are in dark grey colour, whilst DRG controls are in white. (B) Fold Change plot of miRNA levels in the NB (MNA and MNnA collectively considered) vs. DRG comparison. X axis: Average log of Count per Millions; Y axis: log2 Fold Change (FC). miRNAs differentially expressed with p-values < 0.05 are marked as a red dot.

Figure 3 Gene Ontology (GO) analysis of miRNA target genes according to biological process, cellular component and molecular function. (A) GO categories for the predicted gene targets of the up-regulated miRNAs in the NB vs. DRG comparison. (B) GO categories for the predicted gene targets of the down-regulated miRNAs in the NB vs. DRG comparison. All the categories were significantly enriched (FDR < 0.05).

Figure 4 (A) Distribution of different miRNAs with at least 10 read counts in a given biological condition. MYCN-non amplified tumours are in dark grey, whilst MYCN amplified tumours are in white. (B) Validation of miRNA array data by quantitative real-time polymerase chain reaction (Q-PCR). Relative expression levels for miR-18a-5p, miR-217, miR-491-5p and miR-628-3p in MNA (n=11) in comparison to MNnA (n=11) NB cases. Histograms indicate the mean value ± SD of independent tumours. (*, p < 0.05).

Figure 5 (A) Schematic representation of the luciferase construct with a fragment of 880 bp of the MYCN 3’UTR, including the predicted target sequence for mir-628-3p. (B). Luciferase activity in HEK293T cells over-expressing miR-628-3p and the MYCN-3’UTR vector relative to cells transfected with miR-Ctr. Bars represent the mean of two independent experiments ± SD, each carried out in triplicate. (**p < 0.01). (C) Reduction of MYCN protein levels in KCNR cells transiently transfected with miR-628-3p mimics in comparison to miR-Ctr samples. Tubulin was used as loading control. Representative image from three independent experiments. The intensity of the MYCN bands was evaluated by densitometric analysis, normalized on tubulin signal, and reported with respect to untreated cells (miR-Ctr).

Figure 6 Main functional module by GO Biological Process Enrichment Analysis of Functional Interaction Networks from target genes of up-regulated microRNAs (miR-16-2-3p, miR-18a-5p and miR-217) in the MNA vs. MNnA comparison. Diamond-shaped nodes represent transcription factors; round-shaped nodes represent genes; solid lines indicate direct interactions; dashed lines represent indirect relationship. 

Figure 7 Main functional module by GO Biological Process Enrichment Analysis of Functional Interaction Networks from target genes of down-regulated microRNAs (miR-338-5p, miR-489-3p,miR-491-5p, miR-628-3p, miR-628-5p, and miR-3065-3p) in the MNA vs. MNnA comparison. Diamond-shaped nodes represent transcription factors; round-shaped nodes represent genes; solid lines indicate direct interactions; dashed lines represent indirect relationship.






Clinical-pathological features of the analysed tumour cases. Variables were categorized as follows: age at diagnosis (months), MYCN-amplification status, primary site and clinical stage. MYCN-amplified >10; MYCN-non amplified <3. Asterisks indicate samples used for deep sequencing analysis.

Table II
miRNA expression in NB tumours. A. miRNA species expressed at higher levels in NBs (MNA and MNnA are collectively considered) vs. DRG; B. miRNA species expressed at lower levels in NBs (MNA and MNnA are collectively considered) vs. DRG.

Table III
Enriched KEGG pathways of the differentially up-regulated miRNAs’ target genes. Comparison NB vs. DRG. Pathways significantly enriched are reported (FDR < 0.05).

Table IV
Enriched KEGG pathways of the differentially down-regulated miRNAs’ target genes. Comparison NB vs. DRG. Pathways significantly enriched are reported (FDR < 0.05).

Table V
Differentially expressed miRNAs in MNA vs. MNnA NB tumours.

Table VI
Predicted targets of over-expressed miRNAs, involved in DNA repair, apoptotic signalling pathway, FGF receptor signalling pathway, axon guidance, negative regulation of adenylate cyclase activity.

Table VII
Predicted targets of under-expressed miRNAs, involved in TLR signalling pathway, EGFR signalling pathway, synaptic transmission.

Table VIII 
Main modules involved in the functional interaction network built with Cytoscape from the predicted target genes of the selected microRNAs. Mostly enriched Gene Ontology Biological Process (GO BP) in each module with the corresponding p-value and FDR for the target genes of up-regulated (A) and down-regulated (B) miRNAs in the MNA vs. MNnA comparison.
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